{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T16:28:02Z","timestamp":1750696082346,"version":"3.40.5"},"reference-count":9,"publisher":"Cambridge University Press (CUP)","issue":"3","license":[{"start":{"date-parts":[[2019,11,21]],"date-time":"2019-11-21T00:00:00Z","timestamp":1574294400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CNS Spectr."],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1017\/s1092852919001627","type":"journal-article","created":{"date-parts":[[2019,11,21]],"date-time":"2019-11-21T09:26:34Z","timestamp":1574328394000},"page":"185-187","source":"Crossref","is-referenced-by-count":9,"title":["Eculizumab package insert recommendations for meningococcal vaccinations: call for clarity and a targeted approach for use of the drug in neuromyelitis optica spectrum disorder"],"prefix":"10.1017","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2322-503X","authenticated-orcid":false,"given":"Jagannadha","family":"Avasarala","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brent S.","family":"Sokola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Selina","family":"Mullins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"56","published-online":{"date-parts":[[2019,11,21]]},"reference":[{"key":"S1092852919001627_r6","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(13)70076-0"},{"key":"S1092852919001627_r1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1900866"},{"key":"S1092852919001627_r7","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6619a6"},{"key":"S1092852919001627_r4","unstructured":"4. USFDA. Briefing information for the November 18, 2014 meeting of the Drug Safety and Risk Management Advisory Committee (DSaRM). 2014; US FDA Web site, https:\/\/wayback.archive-it.org\/7993\/20170404151101\/ https:\/\/www.fda.gov\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/DrugSafetyandRiskManagementAdvisoryCommittee\/ucm423029.htm. (Accessed July 24, 2019)"},{"key":"S1092852919001627_r2","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-017-8596-7"},{"key":"S1092852919001627_r9","doi-asserted-by":"publisher","DOI":"10.1111\/cei.12388"},{"key":"S1092852919001627_r8","unstructured":"8. Clinical commissioning policy: eculizumab in the treatment of recurrence of C3 glomerulopathypost kidney transplant (all ages); 2017. NHS Web site, https:\/\/www.england.nhs.uk\/wpcontent\/uploads\/2017\/02\/clincomms-policy-16054p.pdf. (Accessed July 24, 2019)"},{"key":"S1092852919001627_r5","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6627e1"},{"key":"S1092852919001627_r3","doi-asserted-by":"publisher","DOI":"10.1086\/431151"}],"container-title":["CNS Spectrums"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S1092852919001627","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,22]],"date-time":"2021-06-22T08:45:53Z","timestamp":1624351553000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S1092852919001627\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,21]]},"references-count":9,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["S1092852919001627"],"URL":"https:\/\/doi.org\/10.1017\/s1092852919001627","relation":{},"ISSN":["1092-8529","2165-6509"],"issn-type":[{"type":"print","value":"1092-8529"},{"type":"electronic","value":"2165-6509"}],"subject":[],"published":{"date-parts":[[2019,11,21]]}}}